The chemokine receptor CCR5 Δ32 allele in natalizumab-treated multiple sclerosis

M Møller; H B Søndergaard; Nils Iørgen Koch-Henriksen; P S Sorensen; F Sellebjerg; A B Oturai

doi:10.1111/ane.12145

The chemokine receptor CCR5 Δ32 allele in natalizumab-treated multiple sclerosis

M Møller, H B Søndergaard, Nils Iørgen Koch-Henriksen, P S Sorensen, F Sellebjerg, A B Oturai

Afdeling for Hjerne- og Nervesygdomme

7 Citationer (Scopus)

Abstract

The chemokine receptor CCR5 may be important for the recruitment of pathogenic T cells to the CNS in multiple sclerosis (MS). We hypothesized that this chemokine receptor might still be important for T-cell migration during treatment with anti-very late antigen (VLA)-4 antibody. We therefore analysed whether natalizumab-treated MS patients carrying the CCR5 Δ32 deletion allele, which results in reduced expression of CCR5 on the cell surface, had lower disease activity.

Originalsprog	Engelsk
Tidsskrift	Acta Neurologica Scandinavica
Vol/bind	129
Udgave nummer	1
Sider (fra-til)	27-31
Antal sider	5
ISSN	0001-6314
DOI	https://doi.org/10.1111/ane.12145
Status	Udgivet - jan. 2014

Adgang til dokumentet

10.1111/ane.12145

Citationsformater

@article{b7f1600b1ad647c7a69f0843b58aa4a5,

title = "The chemokine receptor CCR5 Δ32 allele in natalizumab-treated multiple sclerosis",

abstract = "The chemokine receptor CCR5 may be important for the recruitment of pathogenic T cells to the CNS in multiple sclerosis (MS). We hypothesized that this chemokine receptor might still be important for T-cell migration during treatment with anti-very late antigen (VLA)-4 antibody. We therefore analysed whether natalizumab-treated MS patients carrying the CCR5 Δ32 deletion allele, which results in reduced expression of CCR5 on the cell surface, had lower disease activity.",

author = "M M{\o}ller and S{\o}ndergaard, {H B} and Koch-Henriksen, {Nils I{\o}rgen} and Sorensen, {P S} and F Sellebjerg and Oturai, {A B}",

note = "{\textcopyright} 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.",

year = "2014",

month = jan,

doi = "10.1111/ane.12145",

language = "English",

volume = "129",

pages = "27--31",

journal = "Acta Neurologica Scandinavica",

issn = "0001-6314",

publisher = "Wiley-Blackwell Munksgaard",

number = "1",

}

TY - JOUR

T1 - The chemokine receptor CCR5 Δ32 allele in natalizumab-treated multiple sclerosis

AU - Møller, M

AU - Søndergaard, H B

AU - Koch-Henriksen, Nils Iørgen

AU - Sorensen, P S

AU - Sellebjerg, F

AU - Oturai, A B

PY - 2014/1

Y1 - 2014/1

N2 - The chemokine receptor CCR5 may be important for the recruitment of pathogenic T cells to the CNS in multiple sclerosis (MS). We hypothesized that this chemokine receptor might still be important for T-cell migration during treatment with anti-very late antigen (VLA)-4 antibody. We therefore analysed whether natalizumab-treated MS patients carrying the CCR5 Δ32 deletion allele, which results in reduced expression of CCR5 on the cell surface, had lower disease activity.

AB - The chemokine receptor CCR5 may be important for the recruitment of pathogenic T cells to the CNS in multiple sclerosis (MS). We hypothesized that this chemokine receptor might still be important for T-cell migration during treatment with anti-very late antigen (VLA)-4 antibody. We therefore analysed whether natalizumab-treated MS patients carrying the CCR5 Δ32 deletion allele, which results in reduced expression of CCR5 on the cell surface, had lower disease activity.

U2 - 10.1111/ane.12145

DO - 10.1111/ane.12145

M3 - Journal article

C2 - 23668375

SN - 0001-6314

VL - 129

SP - 27

EP - 31

JO - Acta Neurologica Scandinavica

JF - Acta Neurologica Scandinavica

IS - 1

ER -

The chemokine receptor CCR5 Δ32 allele in natalizumab-treated multiple sclerosis

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater